Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It has long been recognized that dietary factors influence the risk of developing colon cancer, with populations consuming a higher proportion of fruits and vegetables having lower risk. A compound found in the skin of grapes, resveratrol, has been purported to have colon cancer prevention activity though the dosages obtained through the diet have always seemed too low to produce inhibitory effects against cancer cells in the laboratory. We have found that low concentrations of resveratrol inhibit the Wnt pathway, a key signaling pathway which is activated in over 85% of colon cancers. We have also found in a small pilot trial that low dosages of freeze-dried grape powder can directly inhibit Wnt signaling in the normal colon and that grape powder was more effective than resveratrol alone in blocking Wnt throughput. This suggests that components of grapes may have direct activity in inhibiting a key signaling pathway and that this may correlate with cancer prevention activity.
In this study, we will directly test the impact of a diet containing a specific amount of red grapes in the context of a controlled amount of other resveratrol containing foodstuffs on Wnt signaling in the colon. This grape-supplemented diet provides a low-dose of resveratrol in conjunction with other potentially active components contained within the grapes. Participants will be normal volunteers and molecular studies will be done on colon tissue obtained by a limited flexible sigmoidoscopy before, and after, the red grape-containing diet is ingested. Different dosages of grapes will be utilized. This study will define the effect of dietary grape-derived low dose resveratrol on biomarkers related to the Wnt pathway, and provide critical information as to the utility of this nutritional approach toward colon cancer prevention.
For this study, seedless red grapes will be used. Ten participants will be enrolled at each dose level of grapes as follows:
- Dose level 1: 1 lb/day fresh red grapes
- Dose level 2: 2/3 lb/day fresh red grapes
- Dose level 3: 1/3 lb/day fresh red grapes
Participants will be normal volunteers identified through advertisements, referrals, and community outreach.
Primary Objective:
Define the minimum dietarily achievable amount of resveratrol-rich fresh red grapes which are effective in inhibiting Wnt signaling in human colonic mucosa.
Secondary Objectives
- Define whether grape-supplemented diet affects colonic mucosa cell proliferation.
- Define any side-effects associated with the resveratrol-rich dietary program.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- University of California, Irvine Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older, male or female
- Participants must sign informed consent for enrollment
- Participants must have values for tests included in CBC, CMPAN and UA within normal range or no greater than 1.5x ULN or less than 0.75x LLN at prestudy to proceed to registration
- Participants must have normal limited flexible sigmoidoscopic examination on Day 15 to proceed to re-registration
- To receive Day 28 limited flexible sigmoidoscopy, participants must have taken >80% of prescribed dose of red grapes (based on food diary review)
Exclusion Criteria:
- Pregnant or lactating (and/or elevated ßHCG at enrollment)
- Known history of diabetes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Dose Level 1
1 lb/day fresh red grapes
|
1 pound of seedless red grapes
Other Names:
2/3 lb/day fresh red grapes
Other Names:
1/3 lb/day fresh red grapes
Other Names:
|
|
ACTIVE_COMPARATOR: Dose Level 2
2/3 lb/day fresh red grapes
|
1 pound of seedless red grapes
Other Names:
2/3 lb/day fresh red grapes
Other Names:
1/3 lb/day fresh red grapes
Other Names:
|
|
ACTIVE_COMPARATOR: Dose Level 3
1/3 lb/day fresh red grapes
|
1 pound of seedless red grapes
Other Names:
2/3 lb/day fresh red grapes
Other Names:
1/3 lb/day fresh red grapes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Expression and cellular localization of beta-catenin in intestinal mucosa: localization of β-catenin. Expression of Wnt pathway target genes in intestinal mucosa: Wnt target gene expression
Time Frame: 2 yrs
|
2 yrs
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Define whether grape supplemented diet affects colonic mucosa cell proliferation. Ki67 staining method will be utilized on the pre- and post-resveratrol biopsy specimens.
Time Frame: 2 yrs
|
2 yrs
|
|
Define any side-effects associated with the resveratrol-rich dietary program. Laboratory testing is performed at specified timepoints in this protocol, along with history & physical, for the purposes of toxicity monitoring.
Time Frame: 2 yrs
|
2 yrs
|
|
Monitor resveratrol content of grapes throughout the course of the study. Grapes will be obtained from the same source as participants monthly throughout the study and the content of resveratrol will be measured.
Time Frame: 2 yrs
|
2 yrs
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Randall F Holcombe, M.D., University of California, Irvine
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OCRT07046
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.